Abstract Details

Title Surpass Streamline for the Treatment of Heterogenous Size Intracranial Aneurysms: A Multicenter US Real-World Experience

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P1 - Poster Session 1 (9:00 AM-5:00 PM)

Poster/Presentation
Number 098

Objective

To identify the safety and efficacy of Surpass Streamline (SS) according to aneurysm size.

Background Several trials have demonstrated that the treatment of intracranial aneurysm (IA) with flow diverters (FD) is safe and effective. The SS FD approved by the FDA in 2018 is a braided cobalt/chromium alloy implant with 72 or 96 wires.

Design/Methods This is a multicenter, retrospective study for patients treated with the SS FD for IA between January 2018 and June 2021 in the United States. Inclusion criteria: 1. Adults (≥ 18 years) and 2. SS FD treatment for IA. Aneurysms were classified according to dome width in millimeters as follows: < 5 (small); > 5 – 10 (medium), > 10 – 25 (large), > 25 mm (giant). Primary safety outcome was major ipsilateral stroke or neurological death within 12 months. Primary efficacy was complete occlusion percentage assessed with digital subtraction angiography (DSA) at final follow-up.

Results

A total of 210 patients with 210 aneurysms were enrolled. Median age was 59 years, 153 (73%) were females. Most common comorbidity was hypertension in 110 (52%) patients. Smoking history was present in 41 (20%). Headache in 45 (21%) patients was the most common clinical presentation. Incidental aneurysm finding occurred in 91 (43%) cases. Aneurysm location were as follows: 190 (90%) in the anterior circulation and 20 (10%) in the posterior. Aneurysm size categories were as follows: small 129 (61%) small, 74 (36%) medium, 3 (1%) large and 4 (2%) giants. Mean number of SS FD implanted per aneurysm was 1.07 (range 1 – 3). Complete aneurysm occlusion rate was 79% (166) at final follow up. Major stroke and death occurred in 3 (1%) and 1 (0.4%) cases respectively.

Conclusions Our data show that the SS FD has a favorable safety and efficacy profile for the treatment of intracranial aneurysms with different sizes.

Authors/Disclosures
Juan A. Vivanco-Suarez, MD PRESENTER	Mr. Vivanco-Suarez has nothing to disclose.
Mudassir Farooqui, MD	Dr. Farooqui has nothing to disclose.
Milagros Galecio-Castillo, MD	Dr. Galecio-Castillo has nothing to disclose.
	No disclosure on file
	No disclosure on file
	No disclosure on file
David Altschul	No disclosure on file
Johanna T. Fifi, MD, FAAN (Mount Sinai Hospital)	Dr. Fifi has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Stryker, Inc. Dr. Fifi has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Microvention. Dr. Fifi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cerenovus. Dr. Fifi has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Medtronic. Dr. Fifi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Serenity. Dr. Fifi has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MIVI. Dr. Fifi has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Heart Association. Dr. Fifi has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Various law firms. Dr. Fifi has stock in Endostream. Dr. Fifi has stock in Synchron. Dr. Fifi has stock in Imperative Care. Dr. Fifi has stock in Truvic. Dr. Fifi has stock in Bendit. Dr. Fifi has stock in Cerebrotech. Dr. Fifi has stock in Sim&Cure. Dr. Fifi has stock in Q'Apel. The institution of Dr. Fifi has received research support from Viz AI.
Fawaz Al-Mufti, MD (Westchester Medical Center at New York Medical College)	Dr. Al-Mufti has received personal compensation in the range of $0-$499 for serving as a Consultant for Stryker. Dr. Al-Mufti has received personal compensation in the range of $0-$499 for serving as a Consultant for Cerenovus. Dr. Al-Mufti has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Revalesio .
	No disclosure on file
	No disclosure on file
Peter Kan	No disclosure on file
Margarita Rabinovich	No disclosure on file
	No disclosure on file
	No disclosure on file
Ajay Wakhloo	No disclosure on file
Santiago Ortega Gutierrez, MD (University of Iowa)	Dr. Ortega Gutierrez has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for stryker. Dr. Ortega Gutierrez has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for medtronic. Dr. Ortega Gutierrez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medtronic. The institution of Dr. Ortega Gutierrez has received research support from stryker. The institution of Dr. Ortega Gutierrez has received research support from Medtronic. The institution of Dr. Ortega Gutierrez has received research support from Methinks. The institution of Dr. Ortega Gutierrez has received research support from NIH. The institution of Dr. Ortega Gutierrez has received research support from PCORI.

��ɫ��

��ɫ��